Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration joins Pat to chat about the development of PPMD’s Dystrophinopathy Clinical Research Network (DCRN), and the need for a better understanding of long-term safety, efficacy, potential risks and benefits of add-on therapies in this growing landscape of approved and investigational therapies for Duchenne. Together, let’s advance the research evolution.